ITBusinessToday weekly News roundup knowledgework, Microsoft, pulsepoint, Chugai & more. Last updated: August 7, 2026 1:11 pm In Tech news this week... Microsoft has introduced Copilot Cowork, expanding AI-powered workplace automation by enabling intelligent collaboration between employees and AI agents to streamline business operations and improve enterprise productivity. In industrial tech news this week... Microsoft's Copilot Cowork is also reshaping industrial operations by bringing AI-driven automation and collaborative intelligence to manufacturing, engineering, and enterprise workflows, helping organizations accelerate digital transformation. In FinTech news this week... KnowledgeWork has launched its Sales AI Agent Platform, empowering businesses to automate sales workflows, improve customer engagement, and enhance revenue generation through intelligent AI-driven sales operations. In health tech news this week... Phylo has partnered with Chugai to develop an agentic AI platform that accelerates pharmaceutical research, improves drug discovery processes, and supports the future of AI-driven healthcare innovation. In MarTech news this week... PulsePoint has launched an AI-powered marketing platform tailored for the healthcare industry, enabling organizations to deliver more personalized, data-driven, and effective patient engagement campaigns. In gov tech news this week... Japan is planning a secure defense cloud for classified data, strengthening military cybersecurity, digital infrastructure, and secure information sharing to support the country's evolving national defense strategy. Article of the week. Advanced semiconductor packaging is becoming Japan's next competitive advantage, with 3D chip integration technologies enabling higher performance, greater energy efficiency, and the next generation of AI and high-performance computing systems. Stay tuned for more such updates! ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 7, 2026

Phylo has partnered with Chugai Pharmaceutical to deploy Biomni Lab, an AI platform for biomedical research, across Chugai's drug discovery workflows. The collaboration aims to address bottlenecks in drug discovery by consolidating analytical work that is currently slow and fragmented across disconnected tools and datasets. Biomni Lab is an integrated biology environment that combines AI capabilities with hundreds of biomedical resources in one workspace. The platform will support Chugai's research across single-cell analysis, human genetics, disease biology, and target evaluation by connecting with the company's proprietary research data. The partnership follows Biomni's open-source release, which attracted early users from Chugai. The platform is publicly available at phylo.bio, and Chugai joins Phylo's founding customers exploring how AI agents can accelerate drug discovery.

Phylo and Chugai partner to advance AI agents in drug discovery. Phylo announced a collaboration with Chugai Pharmaceutical to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows. South San Francisco, CA & Tokyo, Japan - August 4, 2026 Phylo, Inc. today announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows. This partnership addresses a familiar bottleneck in modern drug discovery: Analytical work behind every research decision is slow and fragmented, forcing scientists to move constantly between disconnected tools, datasets, and methods. As a result, valuable biomedical data too often sits static and underused. As an Integrated Biology Environment, Biomni Lab brings best-in-class AI capabilities and hundreds of biomedical resources into one workspace, giving each Chugai scientist a collaborator across the discovery process. By connecting with proprietary research data inside Chugai's secure environment, Biomni agents turn that data into stronger hypotheses and better-supported decisions, helping Chugai shorten discovery timelines and improve the probability of success in its programs. Biomni Lab will support Chugai's work across multiple areas of drug discovery, including single-cell analysis, human genetics, disease biology, and target evaluation. "We are excited about the opportunity to work with Phylo and explore the capabilities of Biomni Lab in our research environment. As scientific data continues to grow in scale and complexity, scientists need tools designed for the unique challenges of drug discovery research and capable of connecting insights across diverse sources of knowledge. We believe Biomni Lab can help our scientists explore scientific questions more effectively and accelerate our drug discovery to create innovative medicines for patients." - Sohei Oyama, Head of Biological Technology Dept. at Chugai "Chugai's scientists were some of Biomni's earliest users following our open-source release and we're excited to bring our full platform to even more scientists through this partnership. Our vision is to help biopharma become AI-native, and Biomni Lab is built to make that transition practical for discovery teams today. Chugai's longstanding track record of R&D innovation makes it an ideal setting to demonstrate how agentic AI can accelerate breakthrough discovery." - Kexin Huang, Ph.D., Co-Founder & CEO of Phylo Chugai joins Phylo's founding customers, a select group of research organizations defining how agentic AI transforms drug discovery. About Phylo and Biomni Lab. Phylo, Inc. is an applied AI research lab dedicated to agentic biology. The team is building Biomni Lab, an Integrated Biology Environment where scientists work with AI agents to make more discoveries, faster. It is publicly available today at phylo.bio. About Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/.